Table S2. Adverse Events of Any Grade that Occurred in ≥10% of Patients [n (%)]

	Rivoceranib N=80
Patients with any adverse event	80 (100.0)
Hypertension	53 (66.3)
Fatigue	51 (63.8)
Headache	42 (52.5)
Nausea	42 (52.5)
Stomatitis	39 (48.8)
Diarrhoea	35 (43.8)
Decreased appetite	32 (40.0)
Proteinuria	31 (38.8)
Palmar-plantar erythrodysaesthesia syndrome	27 (33.8)
Weight decreased	25 (31.3)
Constipation	23 (28.8)
Aspartate aminotransferase increased	22 (27.5)
Back pain	20 (25.0)
Vomiting	20 (25.0)
Alanine aminotransferase increased	19 (23.8)
Abdominal pain	17 (21.3)
Oral pain	17 (21.3)
Dyspnoea	17 (21.3)
Dysphonia	15 (18.8)
Dry mouth	13 (16.3)
Platelet count decreased	13 (16.3)
Gastrooesophageal reflux disease	13 (16.3)
Blood bilirubin increased	12 (15.0)
Arthralgia	12 (15.0)
Rash	12 (15.0)
Musculoskeletal chest pain	12 (15.0)
Epistaxis	11 (13.8)
Myalgia	10 (12.5)
Dyspepsia	10 (12.5)
Dizziness	10 (12.5)
Oropharyngeal pain	10 (12.5)
Hypokalaemia	10 (12.5)
Anaemia	10 (12.5)
Blood alkaline phosphatase increased	10 (12.5)
Cough	9 (11.3)

	Rivoceranib N=80
Hyponatraemia	8 (10.0)
Hypothyroidism	8 (10.0)
Hypophosphatemia	8 (10.0)